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ABSTRACT.
Purpose: To investigate risk factors for the development and progression of
diabetic retinopathy (DR) and long-term visual outcomes in Dutch patients with
type 1 diabetes mellitus (T1DM).
Methods: Cumulative incidences were calculated for DR, vision-threatening DR
(VTDR), deﬁned as (pre)proliferative DR and diabetic macular oedema, and best-
corrected visual acuity (BCVA) <0.5 and <0.3 at the most recent eye examination.
The following factors were assessed: duration of diabetes, age of onset of T1DM,
gender, mean HbA1c, HbA1c variability (deﬁned as coeﬃcient of variation of ﬁve
separate HbA1c measurements), mean arterial blood pressure, body mass index,
albuminuria and lipid proﬁle. We used multivariable Cox regression models to
identify factors associated with DR development and progression to VTDR.
Results: We found 25-year cumulative incidences of 63% for DR, 21% for VTDR,
2% for BCVA <0.5, and 1% for BCVA <0.3.MeanHbA1c (HR 1.023, p < 0.001),
HbA1c variability (HR 1.054, p < 0.001), age of onset of T1DM (HR 1.024,
p < 0.001),HDLcholesterol (HR0.502, p = 0.002) and total cholesterol (HR1.210,
p = 0.029) showedan independent associationwith faster development of any formof
DR. The mean HbA1c (HR 1.023, p < 0.001) and the presence of albuminuria (HR
2.940, p = 0.028) were associated with faster progression to VTDR.
Conclusion: Thesedata showrelatively lowcumulative incidences ofDR,VTDRand
visual impairment. Higher mean HbA1c, HbA1c variability, age of onset of T1DM
and total cholesterol were independently associated with the risk ofDR development,
and a protective association was found for HDL cholesterol in subjects with
T1DM.MeanHbA1c and presence of albuminuria were associated with progression
of DR.
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Introduction
Diabetic retinopathy (DR) is a poten-
tially sight threatening microvascular
complication of diabetes mellitus
(DM), aﬀecting a third of all DM
patients worldwide (Ding & Wong
2012; Yau et al. 2012). Diabetic
retinopathy (DR) is characterized by
retinal microvascular damage, based
on ischaemic changes and increased
capillary permeability. Visual function
can be aﬀected by diabetic macular
oedema (DME), macular ischaemia or
as sequelae of proliferative diabetic
retinopathy (PDR), notably vitreous
haemorrhage and tractional retinal
detachment. The substantial impact of
DR on visual performance requires
attention to prevention and early detec-
tion of this sight threatening condition.
Diabetic retinopathy (DR) is a com-
plex multifactorial disease and many
risk factors are involved. The most
obvious and important predictive fac-
tor for the development and progres-
sion of DR is hyperglycaemia. The
Diabetes Control and Complications
Trial clearly showed that very intensive
glycaemic control can reduce the inci-
dence of DR by 76% and the progres-
sion of DR by 54% (DCCT, 1993).
Other major systemic risk factors
include hypertension, dyslipidaemia
and high body mass index, although
there is substantial variation in the
consistency and strength of the
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association with these risk factors (Mil-
janovic et al. 2004; Ding &Wong 2012;
Yau et al. 2012). Risk of development
and progression of DR is furthermore
inﬂuenced by a number of non-modiﬁ-
able risk factors, such as duration of
diabetes, pregnancy, puberty and pop-
ulation-based diversity (Raymond
et al. 2009; Yau et al. 2012).
To the best of our knowledge, there
are currently no cohort studies on
development and progression of DR,
and associate risk factors in Dutch
patients with T1DM. The purpose of
this study was to further explore the
risk factors for the development and
progression of DR in this patient
population. In addition, we evaluated




This study was conducted in a cohort
of patients with T1DM who were
recruited at the outpatient diabetes clinic
of the Internal Medicine Department at
the Radboud University Medical Center
between 2006 and 2008 for a study on
hypoglycaemia awareness (Sejling et al.
2016). Patients were eligible for the
current analysis when the DR screen
had take place at the Department of
Ophthalmology of the Radboud
University Medical Center. This study
adhered to the tenets of theDeclaration
of Helsinki, and was approved by the
local Institutional Review Board.
Study participants provided written
informed consent.
Eye determinants
Patients underwent complete ophthal-
mological examinations yearly or more
often in those at high risk of visual
decline. Examinations were standard-
ized and included Snellen best-corrected
visual acuity (BCVA) and retinal eval-
uation with biomicroscopy. In case of
any signs of DR or DME, diagnosis was
conﬁrmed with colour fundus photog-
raphy (Topcon TRC 50 IX, Topcon
Corporation, Tokyo, Japan) and optical
coherence tomography (SpectralisTM
HRA+OCT, Heidelberg Engineering,
Heidelberg, Germany). Stage of DR
and DME were determined according
to the International Clinical Diabetic
Retinopathy Severity Scale (Wilkinson
et al. 2003). The eye with the most
severe retinopathy was included in
further analyses. The two most severe
stages of DR/DME of the Interna-
tional Clinical Diabetic Retinopathy/
Macular Edema Severity Scale were
deﬁned as vision-threatening DR
(VTDR) that is DR corresponding
with the 4-2-1 rule or proliferative
DR, retinal oedema or hard exudates
approaching or involving the fovea.
Non-vision-threatening DR (NVTDR)
was deﬁned as mild or moderate non-
proliferative DR or DME distant from
the fovea.
Visual impairment was deﬁned as a
BCVA <0.3 in the best seeing eye
according WHO International Statisti-
cal Classiﬁcation of Diseases and
Health Problems (WHO, 2015). We
also used BCVA <0.5 as a cut-oﬀ, as
this is below the visual requirement for
a European driving license (European
Union). In addition to the presence of
DR/DME and BCVA, all treatments
which were administered during the
study period were registered.
Data collection
We assessed the variables age at diag-
nosis of T1DM, gender and T1DM
duration from medical charts. Serum
measurements were obtained at ﬁrst
diagnosis of DR, or within 6 months
around the date of the most recent eye
examination in those without DR. The
mean glycated haemoglobin (HbA1c)
level was calculated as the average of 5
measurements at 3-month intervals.
The coeﬃcient of variation (CV), a
measure of HbA1c variability, was cal-
culated from the mean and standard
deviation of the HbA1c measurements
(Luk et al. 2013). Other laboratory mea-
surements were total cholesterol (mmol/
l), high-density lipoprotein (HDL)
cholesterol (mmol/l) and albuminuria
(mg/l). Albuminuria, themost important
marker of diabetic nephropathy, was
deﬁned as a urinary albumin excretion
of ≥30 mg/l in the absence of other
renal pathology (American Diabetes
Association, 2008). The mean arterial
pressure was (MAP, mmHg) assessed
by the equation: MAP ≃ diastolic
blood pressure + ⅓ (systolic blood
pressure – diastolic blood pressure);
body mass index (BMI, kg/m2) was
calculated as weight/height2. Medical
ﬁles were assessed between April and
July 2015.
Statistical analysis
For continuous variables, values were
displayed as mean  standard deviation
(SD) for normal distributions, and as
median with corresponding interquartile
range (IQR) for skewed distributions.
For categorical variables, values were
presented as proportions in percentages.
Binary logistic regression analysis was
used to compare patient characteristics
of the NVTDR group and the VTDR
group with the no DR group. Time of
follow-upwas deﬁnedas the time in years
after ﬁrst diagnosis of diabetes mellitus.
Primary outcome variable was the pres-
ence of DR, secondary outcomes were
VTDR, BCVA <0.5 and BCVA <0.3.
Cumulative incidences of outcome vari-
ables were estimated using the Kaplan–
Meier survival analysis. Values at the
extreme end were pooled due to limited
numbers. Incidence rate was calculated
by dividing the number of new cases by
the total number of person-years.
We used a multiple imputation
approach for randomly missing data
with 20 iterations, incorporating both
determinants and outcome variables.
Multivariable Cox proportional haz-
ards regression was used to identify
predictors for DR and VTDR, with
backward stepwise selection eliminat-
ing variables with p ≥ 0.1. Risks were
displayed as hazard ratios (HR) with
corresponding 95% conﬁdence interval
(CI). Survival curves displaying disease
free fraction were plotted for low- and
high-risk proﬁles. Proﬁles were based
on signiﬁcant variables from the Cox
analyses using cut-oﬀ levels according
to established clinical criteria. For
variables for which standardized refer-
ence levels were not available, 25th and
75th percentiles were used to represent
low and high risk. Using these criteria,
low risk was deﬁned as HbA1c =
53 mmol/mol, total cholesterol = 5.2
mmol/l and HDL = 1.6 mmol/l, HbA1c
variability = 4.9 and age of onset of
T1DM = 15 years. High risk was
deﬁned as HbA1c = 74 mmol/mol, total
cholesterol = 6.2 mmol/l and HDL =
1.0 mmol/mol, HbA1c variability = 9.1
and age of onset of T1DM = 30 years
(DCCT, 1993, National Institutes of
Health, 2001; Feldman et al. 2014).
To obtain insight in the discrimina-
tive ability of our models, a risk score
was calculated for each individual by
multiplying the estimated beta coeﬃ-
cients from multivariate Cox regression
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analysis with the registered data points.
Subsequently, risk scores were catego-
rized and plotted in a histogram for no
DR versus DR, and for NVTDR
versus VTDR. All statistical analyses
were conducted using SPSS version 20
(SPSS, Chicago, IL, USA).
Results
A total of 415 subjects were eligible for
the current study. The follow-up time
varied from 7 to 65 years, with a
median of 29 years. Total number of
patients who developed DR was 284
(68%). Of these, 119 (42%) progressed
to VTDR. Patient characteristics of the
three groups are displayed in Table 1.
As expected, duration of T1DM was
longer in patients with NVTDR and
VTDR than in patients without DR,
and age of T1DM onset was lowest in
the VTDR group. HbA1c determinants
and blood pressure were less favour-
able in the NVTDR and VTDR
groups, and HDL cholesterol was low-
est in VTDR.
The overall incidence rate of DR
was 0.033 per person-years and 0.014
per person-years for VTDR. The 10-
year cumulative incidence of DR was
5%, 20-year cumulative incidence
43%, 25-year cumulative incidence
63%, and 30- and 40-year cumulative
incidences were 75% and 85%. For
VTDR, the 20-year cumulative inci-
dence was 10%, 25-year cumulative
incidence 21%, and 30- and 40-year
cumulative incidences were,
respectively, 34% and 51%. Fifty per
cent of the total study population had
developed DR after 22 years duration
of DM and VTDR after 40 years
(Fig. 1A). With respect to visual acu-
ity, 2% developed BCVA <0.5 after
25 years of T1DM and 28% after
58 years; 1% developed BCVA <0.3
after 25 years of T1DM and 8% after
58 years (Fig. 1B), during which per-
iod the treatments were applied that
are shown in Table S1.
Laboratory assessments which coin-
cided with eye examinations were avail-
able in 380 subjects (126 without DR,
158 NVTDR and 96 VTDR). In the
multivariate Cox regression analysis
based on these subjects, higher age of
onset of T1DM, mean HbA1c, HbA1c
variability, total cholesterol and low
HDL cholesterol were associated with
a faster development of DR (Table 2).
The mean HbA1c and the presence of
albuminuria were associated with a
faster progression of DR to VTDR
(Table 3). We compared the hazard of
DR development for high- and low-
risk proﬁles with Cox regression sur-
vival curves (Fig. 2). Remarkably,
high-risk proﬁles showed a fast decline
in DR free fraction around DM dura-
tion of 20 years, while low-risk proﬁles
showed a gradual decline. With respect
to progression to VTDR, high-risk
proﬁles risks accumulated gradually
after ﬁrst diagnosis of DR to virtually
all aﬀected after >15 years; low-risk
proﬁles only progressed to VTDR in
50% of cases.
Risk scores for the study population
were calculated and plotted in a his-
togram (Fig. S1). Although those
developing DR/VTDR and those who
did not showed somewhat overlapping
risk scores, those with higher risk
scores more often developed DR and
VTDR.
Discussion
In this single centre cohort of subjects
with T1DM, mean HbA1c, HbA1c
variability, HDL cholesterol, total
cholesterol and age of onset of T1DM
were independently associated with the
hazard of developing DR. The mean
HbA1c and albuminuria were associ-
ated with the hazard of progression of
DR to VTDR.
The eﬀect of hyperglycaemia on
development and progression of DR
has been studied thoroughly in previ-
ous research, and our study conﬁrms
the important contribution of HbA1c
(DCCT, 1993; Klein et al. 2008, Yau
et al. 2012). HbA1c variability has
been investigated to a much lesser
extent. Hietala et al. (2013b) and Her-
mann et al. (2014) also reported
HbA1c variability as a risk factor for
development of DR independently of
average glycaemic control. Kilpatrick
(2012) proposed several explanatory
mechanisms for this correlation. For
example, it is possible that with an
increase in HbA1c the risk of microvas-
cular complications rises exponentially;
therefore, people that experience more
Table 1. Patient characteristics
Variables No DR (n = 131) NVTDR (n = 164) VTDR (n = 120)
Age, years 48  37 52  14 56  13*
Male gender, n (%)† 60 (46%) 80 (49%) 55 (46%)
Age of onset of T1DM, years 23  11 21  12 18  13**
Duration of T1DM, years 22  10 32  12** 38  11**
Mean HbA1c, mmol/mol‡ 61 (56–67) 65 (57–72)* 78 (67–89)**
HbA1c variability, CV‡ 5.9 (4.4–8.1) 6.9 (5.0–9.1)* 7.8 (5.8–11.0)**
Mean arterial pressure, mmHg 91  10 95  10* 96  11*
Body mass index, kg/m2‡ 25 (22–27) 26 (23–28) 24 (22–27)
HDL cholesterol, mmol/l 1.56  0.37 1.46  0.42 1.38  0.35*
Total cholesterol, mmol/l 4.9  1.0 4.9  0.8 5.1  1.0
Albuminuria, n (%)† 10 (10%) 7 (7%) 6 (15%)
Data are means  SD.
DR = diabetic retinopathy; NVTDR = non-vision-threatening diabetic retinopathy; VTDR = vision-threatening diabetic retinopathy; n = number;
T1DM = type 1 diabetes mellitus; CV = coeﬃcient of variation; HDL = high-density lipoprotein.
p-values addressed diﬀerences between no DR versus NVTDR/VTDR and were adjusted for age and gender.
* p < 0.05.
** p < 0.001.
† Data are number of subjects with %.
‡ Data are median with interquartile range.
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HbA1c variation are exposed to a
higher average risk. Another possible
explanation is that improving gly-
caemic control can lead to a short-term
‘early worsening’ in retinopathy, before
a subsequent net improvement in the
long term, which is a phenomenon that
has been reported by the Diabetes
Control and Complications Trial
(DCCT, 1998). As a consequence of
the fast alterations in glycaemic con-
trol, the retina may have insuﬃcient
time to recover from the damaging
eﬀects of previously high HbA1c dur-
ing periods where HbA1c is low.
In our study, lower HDL cholesterol
and higher total cholesterol levels were
associated with an increased hazard of
DR development. This eﬀect corrobo-
rates some, but not all studies, as
clinical evidence for a relation between
dyslipidaemia and DR is controversial
(Chang & Wu 2013). The potential
mechanism of action of the association
between lipids and DR is also unclear.
It has been hypothesized that lipopro-
teins leak through the disrupted blood–
retinal barrier and have a cytotoxic
eﬀect on retinal cells (Yu & Lyons
2013). Others hypothesized that
lipoproteins interact with the activation
of protein kinase C and advanced
glycation end product formation –
two pathways involved in DR patho-
physiology (Chang & Wu 2013).
We found that a higher age of onset of
T1DMwas associated with a more rapid
development of DR. This conﬁrms ear-
lier reports of associations between
increasing age of onset of T1DM and
development and progression of DR
(Hammes et al. 2011; Hietala et al.
2013a; Forga et al. 2016). We hypothe-
size that subjects with a higher age of
onset of T1DM develop DR faster,
because the natural ageing process
contributes to retinal degeneration, inde-
pendently of hyperglycaemia. Various
microvascular alterations can be
observed in the ageing retina, such as
increased vessel leakage and declining
retinal pigment epithelium cell integrity
(Van Kirk et al. 2011; Wei et al. 2017).
Additionally, age-related inﬂammatory
changes are believed to contribute to the
pathogenesis of DR (Xu et al. 2009).
This could make patients with an older
age of onset of T1DM more vulnerable
to development of complications.
The link between advanced DR
stages and albuminuria has been well
Fig. 1. Lifetime risk as a function of DM duration for: (A) DR and VTDR; (B) visual impairment. DR = diabetic retinopathy; VTDR = vision-
threatening diabetic retinopathy; DM = diabetes mellitus; BCVA = best-corrected visual acuity.
Table 2. Hazard of developing DR for known risk factors from multivariate Cox regression
analysis
HR 95% CI p-value
Age of onset T1DM (years) 1.024 1.013–1.035 <0.001
Mean HbA1c (mmol/mol) 1.023 1.014–1.033 <0.001
HbA1c variability (CV) 1.054 1.028–1.081 <0.001
HDL cholesterol (mmol/l) 0.502 0.325–0.775 0.002
Total cholesterol (mmol/l) 1.210 1.020–1.436 0.029
HR = hazard ratio; 95% CI = 95% conﬁdence interval; CV = coeﬃcient of variation;
HDL = high-density lipoprotein.
The hazard ratio for continuous variables should be interpreted as hazard per point of increase in
the variable per time unit. For example,: when the HbA1c level increases with 10 points, the
instantaneous risk of DR development is 1.02510 = 1.280 or 28.0% higher.
Table 3. Hazard of developing VTDR for
known risk factors from multivariate Cox
regression analysis




Albuminuria 2.940 1.130–7.648 0.028
HR = hazard ratio; 95% CI = 95% conﬁ-
dence interval.
The hazard ratio for continuous variables
should be interpreted as hazard per point of
increase in the variable per time unit. For
example, when the HbA1c level increases with
10 points, the instantaneous risk of DR pro-
gression is 1.02410 = 1.268 or 26.8% higher.
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established (Cruickshanks et al. 1993;
Klein et al. 2008). However, only few
studies have investigated the relation-
ship between albuminuria and progres-
sion to VTDR in T1DM patients.
Lloyd et al. (1995) reported an associ-
ation between increased albumin excre-
tion rate and progression to
proliferative DR over a 2-year interval.
In contrast, no relationship was found
between albuminuria and DR progres-
sion in two other studies (Lovestam-
Adrian et al. 2001; Klein et al. 2008).
This discrepancy is possibly the result
of a diﬀerent deﬁnition of progression,
as in the latter two studies DR pro-
gression was referred to as an increase
in DR severity level. Further research is
warranted to investigate the discrimi-
native ability of albuminuria as predic-
tor for imminent VTDR in patients
with T1DM.
The 25-year cumulative incidence of
DR development (63%) and progres-
sion to VTDR (21%) were relatively
low when compared the Wisconsin
Epidemiological Study of Diabetic
Retinopathy (WESDR) group who
found rates for 25-year cumulative
incidences of 97% for DR and 42%
for proliferative DR, while Broe et al.
reported 16-year cumulative incidences
of 95% for DR and 31% for prolifer-
ative DR (Klein et al. 2008; Broe et al.
2014). In our cohort, cumulative inci-
dences for BCVA <0.5 and <0.3 were
3% and 1% respectively. The WESDR
group reported a 25-year incidence of
13% for BCVA ≤0.5. A possible expla-
nation for these disparities may lie in
the glycaemic control of the patients in
our cohort. The measured mean HbA1c
level in our cohort was 68  15 mmol/
mol versus 91  22 mmol/mol in the
WESDR, and 81  17 mmol/mol in
the study by Broe et al. (Klein et al.
2010; Broe et al. 2014).
One of the major strengths of this
study was the long duration of follow-
up. The average duration of follow-up
was 29 years, thereby oﬀering good
insight in the rates of development and
progression of DR. Another strength
was the use of ﬁve separate HbA1c
measurements to deﬁne the mean
HbA1c. This makes the HbA1c level a
more reliable parameter and provides a
good reﬂection of HbA1c variability in
the 1-year period prior to diagnosis of
DR or the most recent examination.
The present study also has its limita-
tions, besides the drawbacks that gen-
erally apply to a retrospective study
design. In some instances, information
on a single measurement was extrapo-
lated in time, whereas patients might
have changed their behaviour over time
and the investigated variables may
have been subject to ﬂuctuations. Fur-
thermore, the study population in this
cohort represents a carefully selected
phenotyped tertiary care population
that may not fully reﬂect the general
population.
In conclusion, the current study
provides an overview of the risk factors
that are responsible for development
and progression of DR in patients with
T1DM in a tertiary referral centre. This
adds to the growing body of evidence
that for proper glycaemic control we
should not only focus on absolute
HbA1c levels, but also on the level of
HbA1c variation. We therefore advise
health care professionals involved in
the prevention and early detection of
retinopathy in patients with T1DM, to
take HbA1c variability into account
when optimizing glycaemic control.
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